IDRA 21

IDRA 21 is a positive and orally active modulator of the AMPA receptor. IDRA 21 facilitates excitatory neurotransmission via GluR1/2 receptors. IDRA 21 has the potential for the research of cognitive/memory disorders, including those associated with aging[1].

Product Specifications

CAS Number

[22503-72-6]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

IGluR

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/idra-21.html

Purity

99.66

Solubility

DMSO : 250 mg/mL (ultrasonic)

Smiles

CC(NC1=CC=C(Cl)C=C12)NS2(=O)=O

Molecular Formula

C8H9ClN2O2S

Molecular Weight

232.69

Precautions

H302, H315, H319, H335

References & Citations

[1]Buccafusco JJ, et al. The effects of IDRA 21, a positive modulator of the AMPA receptor, on delayed matching performance by young and aged rhesus monkeys. Neuropharmacology. 2004 Jan;46 (1) :10-22. doi: 10.1016/j.neuropharm.2003.07.002.|[2]Yamada KA, et al. The diazoxide derivative IDRA 21 enhances ischemic hippocampal neuron injury. Ann Neurol. 1998 May;43 (5) :664-9.